Evidence map›Paper›PMID 28272808›Full record

Trial reportClinical cardiology2017

Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.

Jordana K Schmier, Kevin L Ong, Gregg C Fonarow

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080504 (Heart Failure Monitoring With Eko Electronic Stethoscopes), which is not on this map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05080504 completednot on this mapstarted 2021, after this paper: background citation

Heart Failure Monitoring With Eko Electronic Stethoscopes (CardioMEMS)

TypeobservationalSponsorEko Devices, Inc.Ran2021 to 2023Enrolled17ConditionsHeart FailureArmsEko DUO
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Markov modeling for cost-effectiveness using federated health data network.Journal of the American Medical Informatics Association : JAMIA · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jordana K SchmierDepartment of Health Sciences Exponent, Alexandria, Virginia.
Kevin L OngDepartment of Biomedical Engineering, Exponent, Philadelphia, Pennsylvania.
Gregg C FonarowDivision of Cardiology, Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, California.ORCID http://orcid.org/0000-0002-3192-8093
Exponent (United States) · USRonald Reagan UCLA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a leading cause of cardiovascular mortality in the United States and presents a substantial economic burden. A recently approved implantable wireless pulmonary artery pressure remote monitor, the CardioMEMS HF System, has been shown to be effective in reducing hospitalizations among New York Heart Association (NYHA) class III HF patients. The objective of this study was to estimate the cost-effectiveness of this remote monitoring technology compared to standard of care treatment for HF. A Markov cohort model relying on the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) clinical trial for mortality and hospitalization data, published sources for cost data, and a mix of CHAMPION data and published sources for utility data, was developed. The model compares outcomes over 5 years for implanted vs standard of care patients, allowing patients to accrue costs and utilities while they remain alive. Sensitivity analyses explored uncertainty in input parameters. The CardioMEMS HF System was found to be cost-effective, with an incremental cost-effectiveness ratio of $44,832 per quality-adjusted life year (QALY). Sensitivity analysis found the model was sensitive to the device cost and to whether mortality benefits were sustained, although there were no scenarios in which the cost/QALY exceeded $100,000. Compared with standard of care, the CardioMEMS HF System was cost-effective when leveraging trial data to populate the model.

Indexed as

Health Care CostsAgedCost-Benefit AnalysisFollow-Up StudiesHeart FailureHospitalizationHumansMaleMonitoring, PhysiologicRetrospective StudiesTelemetryTime FactorsUnited Statescost effectivenesseconomic analysisheart failuremonitoringquality

Identifiers

PMID28272808
PMCPMC6490396
OpenAlexW2594707227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.